GlobeNewswire Inc.··NaBelite Bio's Tinlarebant Wins Swiss Orphan Drug Status Ahead of FDA Filing
Belite Bio secures Swiss orphan drug status for tinlarebant, advancing rare eye disease treatment toward FDA approval expected Q2 2026.
BLTEFDA approvalStargardt disease